Stability Study of mRNA - Lipid Nanoparticles under Different Formulation and Storage Conditions

Importance of the Topic

Messenger RNA lipid nanoparticles have become a cornerstone of modern biopharmaceuticals, serving as protective delivery vehicles that enhance mRNA stability and enable efficient in vivo gene expression. Ensuring the structural integrity and consistent lipid composition of these nanoparticles is essential for vaccine efficacy and gene therapy safety.

Objectives and Study Overview

This study aimed to develop and validate a high-resolution LC–MS method for simultaneous identification and quantification of key lipid components in mRNA-LNP formulations. The method was then applied to evaluate nanoparticle stability under various formulation parameters and storage temperatures, comparing liquid and lyophilized preparations.

Methodology and Instrumentation

Sample Preparation

• mRNA was encapsulated using microfluidic mixing into LNPs composed of ionizable amino lipid, phospholipid, cholesterol, and PEG-lipid conjugate.
• Formulations included different cryoprotectants (sucrose, mannitol) and storage conditions at −70 °C, −20 °C, 4 °C.

Instrumental Setup

• LC: Agilent 1290 Infinity II with Poroshell 120 phenyl-hexyl column (2.1×50 mm, 1.9 μm); gradient from 100 % 90 % MeOH/10 mM ammonium acetate to 100 % 90 % ACN/10 mM ammonium acetate; flow rate 0.4 mL/min; column temperature 55 °C.
• MS: Agilent 6545XT AdvanceBio LC/Q-TOF in positive AJS ESI mode; mass range 110–1700 m/z; extended dynamic range acquisition.

Results and Discussion

Separation and Identification

• Seven lipids (cholesterol, DOPE, DOTAP, DSPC, SM-102, ALC-0315, DMG-PEG 2K) were baseline resolved and matched theoretical masses within 2.5 ppm.
• Calibration curves exhibited linearity (r²>0.99) over relevant concentration ranges.
• Precision studies showed RSDs <0.5 % for retention times and <1.5 % for peak areas.

Stability Assessment

• Non-lyophilized LNPs displayed significant shifts in lipid molar ratios after 1–4 weeks at −20 °C and 4 °C, regardless of cryoprotectant, indicating limited shelf life in liquid form.
• Lyophilized LNPs retained target lipid ratios over 12 weeks under all tested conditions, with only minor DMG-PEG loss at 4 °C after 4 weeks, demonstrating enhanced long-term stability.

Benefits and Practical Applications

The rapid LC–MS assay enables comprehensive quality control for mRNA-LNP manufacturing by simultaneously quantifying multiple lipid components. It supports formulation optimization, batch release testing, and regulatory compliance in vaccine and gene therapy production.

Future Trends and Potential Applications

• Integration with automated high-throughput platforms for real-time monitoring of nanoparticle batches.
• Adaptation to novel lipid chemistries and multi-component nanocarriers, including targeted and stimuli-responsive systems.
• Expansion into stability studies of lyophilized biologics and combination therapies.

Conclusion

A robust, stability-indicating LC–MS method was successfully developed for reliable lipid profiling of mRNA-LNPs. Lyophilization markedly improved formulation stability, offering a practical path for long-term storage and distribution of mRNA therapeutics.

Reference

1. Albertsen CH, Kulkarni JA, Witzigmann D et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 188:114416 (2022).
2. Varache M, Ciancone M, Couffin AC. Development and validation of a novel UPLC-ELSD method for the assessment of lipid composition of nanomedicine formulation. Int J Pharm. 566:11–23 (2019).